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Abstract
Background Children with neonatal diabetes often present with diabetic ketoacidosis and hence are at risk of cerebral
oedema and subsequent long-term neurological deficits. These complications are difficult to identify because
neurological features can also occur as a result of the specific genetic aetiology causing neonatal diabetes.
Case reports We report two cases of neonatal diabetes where ketoacidosis-related cerebral oedema was the major cause
of their permanent neurological disability. Case 1 (male, 18 years, compound heterozygous ABCC8 mutation) and case
2 (female, 29 years, heterozygous KCNJ11 mutation) presented with severe diabetic ketoacidosis at 6 and 16 weeks of
age. Both had reduced consciousness, seizures and required intensive care for cerebral oedema. They subsequently
developed spastic tetraplegia. Neurological examination in adulthood confirmed spastic tetraplegia and severe disability.
Case 1 is wheelchair-bound and needs assistance for transfers, washing and dressing, whereas case 2 requires
institutional care for all activities of daily living. Both cases have first-degree relatives with the same mutation with
diabetes, who did not have ketoacidosis at diagnosis and do not have neurological disability.
Discussion Ketoacidosis-related cerebral oedema at diagnosis in neonatal diabetes can cause long-term severe
neurological disability. This will give additional neurological features to those directly caused by the genetic aetiology of
the neonatal diabetes. Our cases highlight the need for increased awareness of neonatal diabetes and earlier and better
initial treatment of the severe hyperglycaemia and ketoacidosis often seen at diagnosis of these children.
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Introduction
The main cause of morbidity and mortality in childhood-
onset diabetes is ketoacidosis [1]. The most common serious
complication of diabetic ketoacidosis is cerebral oedema,
which carries significant risk of death (21–24%) and perma-
nent neurological disability (18–35% of survivors) [2–4].
Younger children, especially those aged <2 years, and
children with delayed diagnosis are more likely to present
with diabetic ketoacidosis [5–7].
Ketoacidosis is common in children with neonatal diabetes
who present before 6 months of age [8]. The diagnosis is
often delayed because osmotic symptoms are difficult to
detect in infants. The management of diabetic ketoacidosis is
extremely challenging in infants because of the difficulties in
managing fluid balance. This increases their risk of cerebral
oedema which can cause permanent neurological deficit [9].
It is difficult to determine the contribution of diabetic
ketoacidosis-related complications, such as cerebral oedema,
at the time of diagnosis towards overall neurological mor-
bidity in people with neonatal diabetes. Nine of the 22
genetic aetiologies of neonatal diabetes including the most
common, KCNJ11, may have neurological features attribu-
table to the underlying mutation [10]; therefore, neurological
features in these people may be assumed to be caused by the
underlying genetic aetiology rather than complications at
time of diagnosis. We report two cases with neonatal
diabetes in whom ketoacidosis-related cerebral oedema was
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the major cause of their permanent neurological disability
rather than the underlying genetic aetiology.
Case identification and assessment
Case identification
Our cases were identified from 125 people with neonatal
diabetes (diabetes diagnosed at age <6 months, gestational
age >32 weeks) referred from the UK to Exeter Molecular
Genetic laboratory and confirmed to have monogenic aeti-
ology for their diabetes before December 2015 (Table S1).
There were three cases in whom persistent neurological
features were severe and unexpected for the given mutation
when compared with others in the cohort with the same
mutation or mutations in the same gene and/or compared
with the published literature. Initial identification of these
cases was from the clinical information provided by the
referring physicians based on patients’ health records and
subsequently validated on clinical examination. The clinical
details at the time of diagnosis of diabetes were reviewed
from the hospital clinical records. This was available for two
cases but not for the third case as the early clinical notes had
been destroyed. The third case is therefore not reported.
Neurological and functional assessment
We performed detailed neurological examination on these
cases and assessed their disability using the WHO Disability
Assessment Schedule 2.0 (WHODAS 2.0) [11]. Scores in six
different domains are calculated to give values 0 (no disability
in daily living) to 100 (severe disability) and can be completed
by carers or family members. Family members with the same
mutation who did not present with severe diabetic ketoaci-
dosis were assessed as controls for comparison.
Ethics
This study was given ethical approval by the North Wales
Research Ethics Committee, UK.
Case 1
Early history
Case 1 was born at term and had increased hunger and
frequent wet nappies from 3 weeks of age (Fig. 1a). He was
diagnosed with diabetes at 6 weeks when he presented with
severe dehydration and diabetic ketoacidosis (pH 7.16, blood
glucose 73.2 mmol/l). He had reduced consciousness,
opisthotonus and partial seizures and subsequently aspirated.
He was diagnosed as having cerebral oedema, required
intensive care for 6 days and was hospitalized for 25 days.
At 6 months he had motor developmental delay, bilateral
spasticity and elevated muscle tone. A genetic diagnosis of a
compound heterozygous ABCC8 p.P45L/p.G1401R muta-
tion was made at the age of 8 years and he has been
successfully treated with glibenclamide since then. He
currently takes glibenclamide 5 mg twice a day and has an
HbA1c of 34 mmol/mol (5.3%).
Current functional status
He is now 18 years old and attends a school for the
physically disabled. He uses an electric wheelchair to
mobilize and needs assistance for transfers, washing and
dressing. On examination, there was marked weakness,
increased tone with spasticity, brisk reflexes and contractures
of all limbs. His language skills have developed normally. His
total WHODAS 2.0 score is 57 (96th centile; Fig. 1b).
Family member control
The boy’s younger sister with diabetes has the same genetic
mutation but was diagnosed by capillary blood glucose
testing by her parents at 7 days of age before she had
symptoms or diabetic ketoacidosis. She has normal develop-




Case 2 was born at term. She had polyuria and thrush at
16 weeks of age (Fig. 1a). She was diagnosed with diabetes
when she presented with reduced consciousness, generalized
tonic-clonic seizures and diabetic ketoacidosis (pH 6.95,
glucose 78 mmol/l). She was clinically treated for cerebral
oedema and had recurrent seizures requiring intensive care
for 2 weeks. One month after discharge she developed
What’s new?
• The cases in this report show that children with
neonatal diabetes can sustain irreversible neurological
damage as a result of complications of ketoacidosis at
diagnosis and not just because of the neurological
phenotype caused by genetic mutations.
• Both cases presentedwith diabetic ketoacidosis, required
intensive care and probably developed cerebral oedema,
leading to severe permanent spastic tetraplegia.
• The long-term neurological disability means they need
intensive institutional or home support and so has a
profound impact on their lives.
• Our cases highlight the need for increased awareness of
neonatal diabetes and earlier and better initial treat-
ment of the severe hyperglycaemia and ketoacidosis
often seen at diagnosis of these children.
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spastic tetraplegia (Fig. 1a). A genetic diagnosis of a
heterozygous KCNJ11 p.S3C mutation was made at the
age of 19 years. She was transferred from insulin to
glibenclamide at the age of 27 years and currently takes
glibenclamide 35 mg twice a day and has an HbA1c of
69 mmol/mol (8.5%).
Current functional status
She is now aged 29 years and lives in residential care. She
requires assistance with all activities of daily living. She can
say single words and nod her head for communication.
Examination revealed spasticity and contractures of all
limbs. Her total WHODAS 2.0 score is 78 (99th centile;
Fig. 1b).
Family member control
The girl’s mother was diagnosed with diabetes aged 4 years
after the detection of glycosuria on a routine urine test
without diabetic ketoacidosis. The mother’s genetic diagnosis
was established at 38 years of age after her daughter’s
diagnosis. She has normal developmental milestones and
examination results were normal (Fig. 1a).
Discussion
These cases highlight that neurological disability in neonatal
diabetes can occur as a result of diabetic ketoacidosis-related
complications at diagnosis in addition to being a direct result
of underlying genetic aetiology.
Underlying genetic aetiology is not the major cause of the
neurological disabilities seen in these cases. Both cases were
extremely unwell at diagnosis with cerebral oedema, as
shown by their biochemistry, clinical presentation and the
need for intensive care. The family members with the same
mutation but without diabetic ketoacidosis/cerebral oedema
at presentation did not show any permanent neurological
deficit. There were no other cases with KCNJ11 (n = 44,
excluding the third case that we have not reported here) and
ABCC8 (n = 16) neonatal diabetes who had similar neuro-
logical deficits in our cohort. Children with KCNJ11/ABCC8
(a1) (a2)
(b)
FIGURE 1 (a) Pedigrees of the cases. Information is provided on their mutation status, clinical features at diabetes presentation and their present
neurological condition. Filled symbols are those with diabetes. (b) WHO Disability Assessment Schedule 2.0 (WHODAS 2.0) quality-of-life
questionnaire. Both cases showed high levels of overall disability with most domain scores > 99th centile for the normal population. Case 1 solid
grey, case 2 horizontal lines.
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neonatal diabetes commonly have hypotonia and coordina-
tion difficulties but not the spasticity and increased tone in all
four limbs seen in our cases [12].
Cerebral oedema related to diabetic ketoacidosis is the
likely mechanism for the neurological deficits in these cases.
It is known that cerebral oedema attributable to diabetic
ketoacidosis leads to permanent neurological features, par-
ticularly motor disability, in up to 35% of surviving children
[2–4,13,14]. Both cases fit the clinical criteria for cerebral
oedema [15] and spastic tetraplegia can result from diabetic
ketoacidosis with cerebral oedema or other intracranial
complications of diabetic ketoacidosis [13,14,16–18]. A case
with KCNJ11 neonatal diabetes and neurological deficits
attributable to cerebral oedema has been previously reported
[9]. Although we do not have brain imaging studies for the
cases at the time of diabetic ketoacidosis supporting the
presence of cerebral oedema, this is not required to make a
diagnosis, especially as 40% of cases with clinical cerebral
oedema do not show acute abnormalities on their initial
computed tomography examinations [15]; therefore, it has
been proposed that cerebral oedema in the presence of
diabetic ketoacidosis is a clinical, not a radiological,
diagnosis [15]. The severity of disability in these cases may
be attributable to late recognition of symptoms leading to
severe ketoacidosis, the difficulty of neonatal fluid manage-
ment and the vulnerability of the developing brain.
These two cases show that not all neurological deficits in
people with neonatal diabetes are genetic in origin. This is
particularly relevant to genetic aetiologies where there is a
variable phenotype, such as KCNJ11 and ABCC8 neonatal
diabetes in which ~20% of people have marked neurological
features [8]; therefore, neurological features attributed to the
genetic change may not be the correct explanation for a
person’s condition. This information is also important for
clinicians when communicating the diagnosis to patient and
family members, particularly the likelihood of developing
neurological disability in other family members who have
inherited the same mutation.
In conclusion, long-term neurological morbidity in people
with neonatal diabetes can occur independently of the
underlying genetic mutation because of severe ketoacidosis-
related complications at the time of diagnosis. Our cases
highlight the need for increased awareness of neonatal
diabetes and earlier and better initial treatment of the severe
hyperglycaemia and ketoacidosis often seen at diagnosis of
these children.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Clinical characteristics and genetic aetiology of all
125 patients.
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